Media stories about MYOS Co. common stock (NASDAQ:MYOS) have trended somewhat positive recently, according to Accern. The research group identifies negative and positive press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. MYOS Co. common stock earned a media sentiment score of 0.08 on Accern’s scale. Accern also assigned news headlines about the company an impact score of 47.4276501239034 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Shares of MYOS Co. common stock traded down $0.03, hitting $1.47, during trading hours on Thursday, Marketbeat Ratings reports. The company had a trading volume of 285 shares, compared to its average volume of 56,993. MYOS Co. common stock has a fifty-two week low of $1.03 and a fifty-two week high of $2.38. The firm has a market cap of $10.32 million, a P/E ratio of -2.13 and a beta of 1.50.
MYOS Co. common stock (NASDAQ:MYOS) last issued its quarterly earnings data on Tuesday, March 27th. The company reported ($0.17) EPS for the quarter. MYOS Co. common stock had a negative return on equity of 95.44% and a negative net margin of 959.35%. The company had revenue of $0.16 million during the quarter. analysts forecast that MYOS Co. common stock will post -0.35 EPS for the current fiscal year.
In other MYOS Co. common stock news, CEO Joseph Mannello bought 221,774 shares of MYOS Co. common stock stock in a transaction on Wednesday, April 25th. The shares were bought at an average cost of $1.24 per share, for a total transaction of $274,999.76. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Christopher Pechock bought 80,645 shares of MYOS Co. common stock stock in a transaction on Wednesday, April 25th. The shares were acquired at an average price of $1.24 per share, for a total transaction of $99,999.80. The disclosure for this purchase can be found here. Corporate insiders own 45.70% of the company’s stock.
About MYOS Co. common stock
MYOS RENS Technology Inc, a bionutrition and biotherapeutics company, focuses on the discovery, development, and commercialization of nutritional and therapeutic products for maintaining and enhancing the health and performance of muscle tissue. The company primarily focuses on developing the products that enhance muscle health and function essential to the management of sarcopenia, cachexia, and degenerative muscle diseases, and as an adjunct to the treatment of obesity.
Receive News & Ratings for MYOS Co. common stock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MYOS Co. common stock and related companies with MarketBeat.com's FREE daily email newsletter.